


Serial No.  
Filed:

**In the Claims:**

1. (Currently Amended) A ~~compound~~ compound of formula (I)



wherein

$R^1$  is lower alkyl, ~~aryl, substituted aryl, heteroaryl, substituted heteroaryl,~~ or lower alkyl substituted by cycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;

$R^2$ ,  $R^3$  and  $R^4$  are each independently hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy or lower alkenyl, wherein lower alkyl, lower alkoxy and lower alkenyl are optionally substituted by lower alkoxycarbonyl, aryl, substituted aryl, heterocyclyl or substituted heterocyclyl;

$R^5$  is hydrogen, fluorine, lower alkyl, aryl or substituted aryl;

$R^6$  is hydrogen, lower alkyl or hydroxy-lower alkyl, or

$R^5$  and  $R^6$  together with the carbon atoms to which they are attached form a five or six membered saturated carbocyclic ring;

$R^7$  is hydrogen, fluorine or lower alkyl;

wherein substituted aryl is aryl that is mono-, di- or tri-substituted by lower alkyl, lower alkoxy, halo, cyano, azido, amino, di-lower alkyl amino or hydroxy;

substituted heteroaryl is heteroaryl that is mono-, di- or tri-substituted by halogen, amino, perfluoro-lower alkyl, lower alkyl or lower alkoxy;

substituted heterocyclyl is heterocyclyl that is mono-, di- or tri-substituted by lower alkyl, lower alkoxy, halo, cyano, azido, amino, di-lower alkyl amino or hydroxyl;

and pharmaceutically acceptable salts thereof;

Serial No.  
Filed:

with the exception of *rac*-3 $\beta$ -Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\beta$ -ylamine dihydrochloride and *rac*-3 $\beta$ -Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\alpha$ -ylamine dihydrochloride.

2. (Original) The compound according to claim 1, wherein R<sup>1</sup> is lower alkyl, aryl, substituted aryl, or lower alkyl substituted by cycloalkyl, aryl or substituted aryl; R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are each independently hydrogen, hydroxy, lower alkyl, lower alkoxy or lower alkenyl, wherein lower alkyl, lower alkoxy and lower alkenyl are optionally substituted by lower alkoxycarbonyl, aryl, substituted aryl, heterocyclyl, or substituted heterocyclyl; R<sup>5</sup> and R<sup>6</sup> are each independently hydrogen, lower alkyl, aryl, substituted aryl, or, together with the carbon atoms to which they are attached form a five or six membered saturated carbocyclic ring.

3. (Canceled)

4. (Currently Amended) The compound according to claim 13, wherein R<sup>1</sup> is lower alkyl or lower alkyl substituted by cycloalkyl.

5. (Canceled)

6. (Original) The compound according to claim 1, wherein R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are each independently hydrogen, hydroxy, lower alkoxy; or lower alkoxy substituted by aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, or lower alkoxycarbonyl.

7. (Original) The compound according to claim 6, wherein R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are each independently lower alkoxy substituted by phenyl or phenyl substituted by di-lower alkyl amino or cyano.

8. (Currently Amended) The compound according to claim 6, wherein R<sup>2</sup> is lower alkoxy.

Serial No.  
Filed:

9. (Currently Amended) The compound according to claim 6, wherein R<sup>3</sup> is lower alkoxy, hydrogen, hydroxy; or lower alkoxy substituted by aryl, substituted aryl, heterocyclyl, substituted heterocyclyl or lower alkoxycarbonyl.

10. (Original) The compound according to claim 9, wherein R<sup>3</sup> is lower alkoxy, hydrogen or hydroxy.

11. (Currently Amended) The compound according to claim 6, wherein R<sup>4</sup> is lower alkoxy, hydrogen or hydroxy.

12. (Original) The compound according to claim 1, wherein R<sup>5</sup> and R<sup>6</sup> are hydrogen or, together with the carbon atoms to which they are attached, form a six membered saturated carbocyclic ring.

13. (Currently Amended) The compound according to claim 1, selected from the group consisting of:

*rac*-9,10-dimethoxy-3 $\beta$ -propyl-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\beta$ -ylamine,

*rac*-9,10-dimethoxy-3 $\beta$ -(3-methyl-butyl)-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\alpha$ -ylamine,

*rac*-3 $\beta$ -cyclopropylmethyl-9,10-dimethoxy-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\beta$ -ylamine,

*rac*-7 $\beta$ -butyl-11,12-dimethoxy-2,3,4,4a,6,7,8,9,9a,13b $\beta$ -decahydro-1H-pyrido[1,2-f]phenanthridin-8 $\beta$ -ylamine,

*rac*-3 $\beta$ -butyl-9,10-dimethoxy-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\alpha$ -ylamine chlorohydrate (1:2),

*rac*-9,10-dimethoxy-3 $\beta$ -propyl-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\beta$ -ylamine chlorohydrate (1:2),

*rac*-7 $\beta$ -butyl-11,12-dimethoxy-2,3,4,4a,6,7,8,9,9a,13b $\beta$ -decahydro-1H-pyrido[1,2-f]phenanthridin-8 $\beta$ -ylamine chlorohydrate (1:2),

*rac*-2 $\beta$ -amino-3 $\beta$ -butyl-10-methoxy-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-9-

Serial No.  
Filed:

ol chlorohydrate (1:2),

*rac*-2 $\alpha$ -amino-3 $\beta$ -butyl-10-methoxy-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-9-ol chlorohydrate (1:2),

*rac*-2 $\beta$ -amino-3 $\beta$ -butyl-10-methoxy-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-9-ol, and

*rac*-2 $\alpha$ -amino-3 $\beta$ -butyl-10-methoxy-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-9-ol, and;

~~*rac*-9,10-dimethoxy-3 $\beta$ -phenyl-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ylamine.~~

or a pharmaceutically acceptable salt thereof.

14. (Original) The compound according to claim 1, selected from the group consisting of:

*rac*-9,10-dimethoxy-3 $\beta$ -(3-methyl-butyl)-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\alpha$ -ylamine,

*rac*-7 $\beta$ -butyl-11,12-dimethoxy-2,3,4,4a,6,7,8,9,9a,13b $\beta$ -decahydro-1H-pyrido[1,2-f]phenanthridin-8 $\beta$ -ylamine,

*rac*-3 $\beta$ -butyl-9,10-dimethoxy-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\alpha$ -ylamine chlorohydrate (1:2),

*rac*-7 $\beta$ -butyl-11,12-dimethoxy-2,3,4,4a,6,7,8,9,9a,13b $\beta$ -decahydro-1H-pyrido[1,2-f]phenanthridin-8 $\beta$ -ylamine chlorohydrate (1:2),

*rac*-2 $\alpha$ -amino-3 $\beta$ -butyl-10-methoxy-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-9-ol chlorohydrate (1:2),

*rac*-2 $\alpha$ -amino-3 $\beta$ -butyl-10-methoxy-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-9-ol, and

*rac*-9,10-dimethoxy-3 $\beta$ -phenyl-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ylamine.

15. (Currently Amended) The compound according to claim 1, selected from the group consisting of:

Serial No.

Filed:

~~*rac*-9,10-Dimethoxy-3 $\beta$ -pyrrol-1-yl-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\alpha$ -ylamine,~~

~~*rac*-9,10-Dimethoxy-3 $\beta$ -*p*-tolyl-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\beta$ -ylamine,~~

~~*rac*-9,10-Dimethoxy-3 $\beta$ -*p*-tolyl-1,3,4,6,7,11b $\alpha$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\alpha$ -ylamine,~~

~~*rac*-9,10-dimethoxy-3 $\beta$ -(3,4-dimethyl-phenyl)-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\beta$ -ylamine chlorohydrate (1:2),~~

~~*rac*-9,10-dimethoxy-3 $\beta$ -(3,4-Dimethyl-phenyl)-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\alpha$ -ylamine chlorohydrate (1:2),~~

~~*rac*-9,10-Dimethoxy-3 $\beta$ -(3-methoxy-phenyl)-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\beta$ -ylamine chlorohydrate (1:2),~~

~~*rac*-9,10-Dimethoxy-3 $\beta$ -(3-methoxy-phenyl)-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\alpha$ -ylamine chlorohydrate (1:2),~~

~~*rac*-9,10-Dimethoxy-3 $\beta$ -pyridin-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\beta$ -ylamine chlorohydrate (1:2),~~

~~*rac*-9,10-Dimethoxy-3 $\beta$ -pyridin-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\alpha$ -ylamine chlorohydrate (1:2),~~

*rac*-4-(2 $\beta$ -Amino-3 $\beta$ -butyl-9,10-dimethoxy-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-7 $\beta$ -yl)-phenol,

*rac*-3 $\beta$ -Butyl-9,10-dimethoxy-6-methyl-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ylamine,

*rac*-3 $\beta$ -Butyl-7 $\beta$ -(4-chloro-phenyl)-9,10-dimethoxy-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\alpha$ -ylamine,

*rac*-3 $\beta$ -Butyl-7 $\alpha$ -(4-chloro-phenyl)-9,10-dimethoxy-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\alpha$ -ylamine,

*rac*-3 $\beta$ -Butyl-7 $\beta$ -(3,4-dimethoxy-phenyl)-9,10-dimethoxy-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\alpha$ -ylamine,

Serial No.

Filed:

*rac*-3 $\beta$ -Butyl-9,10-dimethoxy-7,7-dimethyl-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\alpha$ -ylamine,

*rac*-3 $\beta$ -Butyl-9,10-dimethoxy-7,7-dimethyl-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\beta$ -ylamine,

*rac*-7 $\beta$ -Butyl-11,12-dimethoxy-2,3,4,4a $\beta$ ,6,7,8,9,9a $\alpha$ ,13b $\beta$ -decahydro-1H-pyrido[1,2-f]phenanthridin-8 $\beta$ -ylamine,

*rac*-7 $\beta$ -Butyl-11,12-dimethoxy-2,3,4,4a $\beta$ ,6,7,8,9,9a $\alpha$ 13b $\beta$ -decahydro-1H-pyrido[1,2-f]phenanthridin-8 $\alpha$ -ylamine,

*rac*-3 $\beta$ -Butyl-7 $\alpha$ -(3,4-dimethoxy-phenyl)-9,10-dimethoxy-6 $\alpha$ -methyl-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ylamine,

*rac*-7 $\beta$ -Butyl-11,12-dimethoxy-13b-methyl-2,3,4,4a $\beta$ ,6,7,8,9,9a,13b-decahydro-1H-pyrido[1,2-f]phenanthridin-8 $\beta$ -ylamine,

~~*rac*-9,10-Dimethoxy-3 $\alpha$ -phenyl-1,3,4,6,7,11b $\alpha$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\alpha$ -ylamine,~~

~~*rac*-9,10-Dimethoxy-3 $\alpha$ -phenyl-1,3,4,6,7,11b $\alpha$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\beta$ -ylamine,~~

~~9,10-Dimethoxy-3 $\alpha$ -phenyl-1,3,4,6,7,11b $\alpha$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\alpha$ -ylamine,~~

~~9,10-Dimethoxy-3 $\alpha$ -phenyl-1,3,4,6,7,11b $\alpha$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\beta$ -ylamine,~~

~~9,10-Dimethoxy-3 $\beta$ -phenyl-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\beta$ -ylamine,~~

~~9,10-Dimethoxy-3 $\beta$ -phenyl-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\alpha$ -ylamine,~~

(6S)-(2-Amino-3-butyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-6-yl)-methanol,

*rac*-4-(2 $\beta$ -Amino-3 $\beta$ -butyl-9,10-dimethoxy-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-7-yl)-phenol-hydrochloride,

*rac*-4-(2 $\beta$ -Amino-3 $\beta$ -butyl-9,10-dimethoxy-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-7 $\beta$ -yl)-phenol-hydrochloride,

*rac*-3 $\beta$ -Butyl-9,10-dimethoxy-6-methyl-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ylamine-hydrochloride,

Serial No.

Filed:

*rac*-3 $\beta$ -Butyl-7 $\beta$ -(4-chloro-phenyl)-9,10-dimethoxy-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\alpha$ -ylamine-hydrochloride,

*rac*-3 $\beta$ -Butyl-7 $\alpha$ -(4-chloro-phenyl)-9,10-dimethoxy-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\alpha$ -ylamine-hydrochloride,

*rac*-3 $\beta$ -Butyl-7 $\beta$ -(3,4-dimethoxy-phenyl)-9,10-dimethoxy-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\alpha$ -ylamine-hydrochloride,

*rac*-3 $\alpha$ -Butyl-7 $\beta$ -(3,4-dimethoxy-phenyl)-9,10-dimethoxy-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\beta$ -ylamine-hydrochloride,

*rac*-3 $\beta$ -Butyl-7 $\beta$ -(3,4-dimethoxy-phenyl)-9,10-dimethoxy-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\beta$ -ylamine-hydrochloride,

*rac*-3 $\beta$ -Butyl-7 $\alpha$ -(3,4-dimethoxy-phenyl)-9,10-dimethoxy-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\alpha$ -ylamine-hydrochloride,

*rac*-3 $\beta$ -Butyl-9,10-dimethoxy-7 $\beta$ -(4-methoxy-phenyl)-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\alpha$ -ylamine-hydrochloride,

*rac*-3 $\beta$ -Butyl-9,10-dimethoxy-7 $\beta$ -(4-methoxy-phenyl)-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\beta$ -ylamine-hydrochloride,

*rac*-3 $\beta$ -Butyl-9,10-dimethoxy-7,7-dimethyl-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\alpha$ -ylamine-hydrochloride,

*rac*-3 $\beta$ -Butyl-9,10-dimethoxy-7,7-dimethyl-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2 $\beta$ -ylamine-hydrochloride,

*rac*-7 $\beta$ -Butyl-11,12-dimethoxy-2,3,4,4a $\beta$ ,6,7,8,9,9a $\alpha$ ,13b $\beta$ -decahydro-1H-pyrido[1,2-f]phenanthridin-8 $\beta$ -ylamine-hydrochloride,

*rac*-7 $\beta$ -Butyl-11,12-dimethoxy-2,3,4,4a $\beta$ ,6,7,8,9,9a $\alpha$ ,13b $\beta$ -decahydro-1H-pyrido[1,2-f]phenanthridin-8 $\alpha$ -ylamine-hydrochloride, and

*rac*-3 $\beta$ -Butyl-7 $\alpha$ -(3,4-dimethoxy-phenyl)-9,10-dimethoxy-6 $\alpha$ -methyl-1,3,4,6,7,11b $\beta$ -hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ylamine-hydrochloride;

or a pharmaceutically acceptable salt thereof.

Serial No.  
Filed:

16. (Original) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

17. (Currently Amended) A method for the treatment or prophylaxis of diabetes or non-insulin dependent diabetes mellitus, which comprises administering to a patient in need of treatment a compound according to claim 1 in an amount of from about 1 to 1000 mg per day.

18. (Original) The method according to claim 17, wherein the amount administered is a daily dosage of from about 1 to 100 mg.